By Judith E. Karp
This is a well timed compilation of recent recommendations within the molecular pathogenesis and molecular remedy of acute myelogenous leukemia (AML). the focal point is on chosen serious molecular determinants of AML pathogenesis and pathophysiology and the exploitation of those components via assorted healing brokers and modalities. there's an emphasis all through at the bidirectional move of information among the scientific and laboratory arenas.
Read Online or Download Acute Myelogenous Leukemia (Contemporary Hematology) PDF
Similar hematology books
A realistic, easy-to-use advisor to leukemias and lymphomas, figuring out Leukemia and Lymphoma is a useful textual content for everybody concerned with those stipulations, from experts in education to sufferers. utilizing easy terminology and vast colour figures to explain and illustrate the present systems considering analysis and remedy, this can be a prepared resource of contemporary info on those universal stipulations.
Univ. of Oxford, united kingdom. A synthesis of the present wisdom approximately thalassaemia, taking inventory of the sector to determine what has been accomplished and what the long run may perhaps carry. comprises ancient historical past at the box, and assurance of the biology of the thalassaemias. colour and halftone illustrations. For clinicians and researchers.
The significance of bone marrow transplantation for sufferers who do not need a matched sibling donor can't be overvalued. This topic has consistently been within the public area, accentuated via dramatic appeals, every now and then, to look for matched volunteer donors within the public at huge. regrettably, the provision of such donors is restricted, because of the awesome genetic variety of people.
Offers a accomplished photo of care, together with diagnostic, healing, and psychosocial points. The individuals conceal uncomplicated technology and epidemiological features of the general public wellbeing and fitness problem, yet hold a spotlight at the everyday matters encountered in facing affected humans. Containing transparent, sensible suggestion, this article is a vital, useful source to bridge the distance among pricey reference texts and smaller manuals.
- Hodgkin Lymphoma
- Hodgkin's and Non-Hodgkin's Lymphoma (Cancer Treatment and Research)
- The Jak-Stat Pathway in Hematopoiesis and Disease (Molecular Biology Intelligence Unit, 20)
- Human blood plasma proteins: structure and function
Additional info for Acute Myelogenous Leukemia (Contemporary Hematology)
122. O'Farrell AM, Foran IM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9(15): 5465-5476. 123. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105(1):54-60. 124. Smith BD, Levis M, Beran M, Small D, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biological and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Oncoprotein s are expected to contribute to myeloid transformation by inhibiting myeloid differentiation. 1, cytokine receptors, MPO, and other early myeloid genes, by inhibiting apopto sis, via induction of bcl-2 in cooperation with nuclear factor (NF)-KB pSO, and by having reduced ability to inhibit G l-to-S progression. or by competitively inhibiting binding to cis DNA elements. l promoters (108,113). In addition , because the C/EBPa N-terminus is required for inhibition of the cell cycle in fibroblast cells, loss of this region may enable C/EBPap30 to block differentiation without slowing proliferation.
Blood 2001 ;98:623. 133. Lancet IE, Karp IE, Gotlib J, et al. Zamestra (RI15777) in previously untreated poor-risk AML and MDS: Preliminary results of a phase II trial. Blood 2002;100:560a. 134. Zimmerman TM, Harlin H, Odenike OM, et al. Dose-ranging pharmacodynamic study oftipifamib (RI15777) in patients with relapsed and refractory hematological malignancies. J Clin Oncol 2004;22(23):4816-4822. 135. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biological activities in the phase I setting.